An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections

Pierre Delpech, Muna Aleryan, Brian Jones, Curtis Gemmell, Susan Lang

Research output: Contribution to journalArticle

20 Downloads (Pure)

Abstract

Skin and soft tissue infections (SSTI) are among the most commonly occurring infections and evidence suggests that these are increasing world-wide. The aetiology is diverse, but Staphylococcus aureus predominate and these are often resistant to antimicrobials that were previously effective. Tedizolid is a new oxazolidinone-class antibacterial indicated for the treatment of adults with SSTI caused by Gram-positive pathogens, including S. aureus.

The aim of this study was to evaluate the in vitro efficacy of tedizolid in comparison to other clinically used antibacterials against antibiotic sensitive- and resistant-staphylococci, grown in planktonic cultures and as biofilms reflecting the growth of the microorganism during episodes of SSTI.

Against a panel of 66 clinical staphylococci, sensitivity testing revealed that a lower concentration of tedizolid was required to inhibit the growth of staphylococci compared to linezolid, vancomycin and daptomycin; with the tedizolid MIC50 being 8-fold (S. aureus) or 4-fold (S. epidermidis) below that obtained for linezolid. In addition, cfr+ linezolid-resistant strains remained fully susceptible to tedizolid. Against S. aureus biofilms, 10×MIC tedizolid was superior or comparable with 10×MIC comparator agents in activity, and superior to 10×MIC linezolid against those formed by S. epidermidis (65 vs. 33% reduction, respectively). Under flow-conditions both oxazolidinones at 10×MIC statistically out-performed vancomycin in their ability to reduce the viable cell count within a S. aureus biofilm with fewer the 12% of cells surviving compared to 63% of cells.

In conclusion, tedizolid offers a realistic lower-dose alternative agent to treat staphylococcal SSTI, including infections caused by multi-drug resistant strains.
Original languageEnglish
JournalDiagnostic Microbiology and Infectious Disease
Volume91
Issue number1
Early online date4 Jan 2018
DOIs
Publication statusPublished - May 2018

Fingerprint

Linezolid
Soft Tissue Infections
Staphylococcus aureus
Biofilms
Skin
Staphylococcus
Oxazolidinones
Vancomycin
Daptomycin
Growth
Infection
Cell Count
In Vitro Techniques
Anti-Bacterial Agents

Keywords

  • tedizolid
  • skin and soft tissue
  • infections

Cite this

Delpech, Pierre ; Aleryan, Muna ; Jones, Brian ; Gemmell, Curtis ; Lang, Susan. / An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections. In: Diagnostic Microbiology and Infectious Disease. 2018 ; Vol. 91, No. 1.
@article{6889d8c9f50343f493dbea96b3230cdf,
title = "An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections",
abstract = "Skin and soft tissue infections (SSTI) are among the most commonly occurring infections and evidence suggests that these are increasing world-wide. The aetiology is diverse, but Staphylococcus aureus predominate and these are often resistant to antimicrobials that were previously effective. Tedizolid is a new oxazolidinone-class antibacterial indicated for the treatment of adults with SSTI caused by Gram-positive pathogens, including S. aureus. The aim of this study was to evaluate the in vitro efficacy of tedizolid in comparison to other clinically used antibacterials against antibiotic sensitive- and resistant-staphylococci, grown in planktonic cultures and as biofilms reflecting the growth of the microorganism during episodes of SSTI. Against a panel of 66 clinical staphylococci, sensitivity testing revealed that a lower concentration of tedizolid was required to inhibit the growth of staphylococci compared to linezolid, vancomycin and daptomycin; with the tedizolid MIC50 being 8-fold (S. aureus) or 4-fold (S. epidermidis) below that obtained for linezolid. In addition, cfr+ linezolid-resistant strains remained fully susceptible to tedizolid. Against S. aureus biofilms, 10×MIC tedizolid was superior or comparable with 10×MIC comparator agents in activity, and superior to 10×MIC linezolid against those formed by S. epidermidis (65 vs. 33{\%} reduction, respectively). Under flow-conditions both oxazolidinones at 10×MIC statistically out-performed vancomycin in their ability to reduce the viable cell count within a S. aureus biofilm with fewer the 12{\%} of cells surviving compared to 63{\%} of cells.In conclusion, tedizolid offers a realistic lower-dose alternative agent to treat staphylococcal SSTI, including infections caused by multi-drug resistant strains.",
keywords = "tedizolid, skin and soft tissue, infections",
author = "Pierre Delpech and Muna Aleryan and Brian Jones and Curtis Gemmell and Susan Lang",
note = "Acceptance in SAN AAM: 12m embargo",
year = "2018",
month = "5",
doi = "10.1016/j.diagmicrobio.2018.01.006",
language = "English",
volume = "91",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier B.V.",
number = "1",

}

An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections. / Delpech, Pierre; Aleryan, Muna; Jones, Brian; Gemmell, Curtis ; Lang, Susan.

In: Diagnostic Microbiology and Infectious Disease, Vol. 91, No. 1, 05.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections

AU - Delpech, Pierre

AU - Aleryan, Muna

AU - Jones, Brian

AU - Gemmell, Curtis

AU - Lang, Susan

N1 - Acceptance in SAN AAM: 12m embargo

PY - 2018/5

Y1 - 2018/5

N2 - Skin and soft tissue infections (SSTI) are among the most commonly occurring infections and evidence suggests that these are increasing world-wide. The aetiology is diverse, but Staphylococcus aureus predominate and these are often resistant to antimicrobials that were previously effective. Tedizolid is a new oxazolidinone-class antibacterial indicated for the treatment of adults with SSTI caused by Gram-positive pathogens, including S. aureus. The aim of this study was to evaluate the in vitro efficacy of tedizolid in comparison to other clinically used antibacterials against antibiotic sensitive- and resistant-staphylococci, grown in planktonic cultures and as biofilms reflecting the growth of the microorganism during episodes of SSTI. Against a panel of 66 clinical staphylococci, sensitivity testing revealed that a lower concentration of tedizolid was required to inhibit the growth of staphylococci compared to linezolid, vancomycin and daptomycin; with the tedizolid MIC50 being 8-fold (S. aureus) or 4-fold (S. epidermidis) below that obtained for linezolid. In addition, cfr+ linezolid-resistant strains remained fully susceptible to tedizolid. Against S. aureus biofilms, 10×MIC tedizolid was superior or comparable with 10×MIC comparator agents in activity, and superior to 10×MIC linezolid against those formed by S. epidermidis (65 vs. 33% reduction, respectively). Under flow-conditions both oxazolidinones at 10×MIC statistically out-performed vancomycin in their ability to reduce the viable cell count within a S. aureus biofilm with fewer the 12% of cells surviving compared to 63% of cells.In conclusion, tedizolid offers a realistic lower-dose alternative agent to treat staphylococcal SSTI, including infections caused by multi-drug resistant strains.

AB - Skin and soft tissue infections (SSTI) are among the most commonly occurring infections and evidence suggests that these are increasing world-wide. The aetiology is diverse, but Staphylococcus aureus predominate and these are often resistant to antimicrobials that were previously effective. Tedizolid is a new oxazolidinone-class antibacterial indicated for the treatment of adults with SSTI caused by Gram-positive pathogens, including S. aureus. The aim of this study was to evaluate the in vitro efficacy of tedizolid in comparison to other clinically used antibacterials against antibiotic sensitive- and resistant-staphylococci, grown in planktonic cultures and as biofilms reflecting the growth of the microorganism during episodes of SSTI. Against a panel of 66 clinical staphylococci, sensitivity testing revealed that a lower concentration of tedizolid was required to inhibit the growth of staphylococci compared to linezolid, vancomycin and daptomycin; with the tedizolid MIC50 being 8-fold (S. aureus) or 4-fold (S. epidermidis) below that obtained for linezolid. In addition, cfr+ linezolid-resistant strains remained fully susceptible to tedizolid. Against S. aureus biofilms, 10×MIC tedizolid was superior or comparable with 10×MIC comparator agents in activity, and superior to 10×MIC linezolid against those formed by S. epidermidis (65 vs. 33% reduction, respectively). Under flow-conditions both oxazolidinones at 10×MIC statistically out-performed vancomycin in their ability to reduce the viable cell count within a S. aureus biofilm with fewer the 12% of cells surviving compared to 63% of cells.In conclusion, tedizolid offers a realistic lower-dose alternative agent to treat staphylococcal SSTI, including infections caused by multi-drug resistant strains.

KW - tedizolid

KW - skin and soft tissue

KW - infections

U2 - 10.1016/j.diagmicrobio.2018.01.006

DO - 10.1016/j.diagmicrobio.2018.01.006

M3 - Article

VL - 91

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 1

ER -